HIST — HistSHOCK & HistSHOCK CDx

EpiDisease is offering a breakthrough blood-based IVD test (HistSHOCK) that measures circulating histones H3 and H2B to diagnose sepsis (Sn 77%, Sp 89%), predict progression to septic shock (Sn 83%, Sp 73%), and forecast DIC — addressing a $1.1B diagnostic market with no existing sepsis-specific biomarker.

https://epidisease.com/en/2023/05/01/breakthrough-in-early-sepsis-detection-and-stratification-of-patients/

A RWE clinical performance trial in 450 ICU patients across four national reference centres has just been finished, with CE-IVD submission planned for 2027.

HistSHOCK CDx is additionally positioned as a companion diagnostic for anti-histone therapies currently in Phase II trials (Matisse Pharmaceuticals, M6229, Phase I terminated in 2025), targeting a $16B+ SAM.

https://epidisease.com/en/2025/08/28/epidisease-receives-funding-to-advance-the-development-of-is-companion-diagnostic-tests-histshock-cdx/

We are actively seeking pharma co-development partnerships, CDx collaboration agreements, and out-licensing or IP sale discussions with established diagnostics or critical care players.